Albert David Limited ALBERTDAVD NSEPHARMA
Company Overview
Albert David Limited manufactures and trades in pharmaceutical formulations, infusion solutions, herbal dosage forms, and bulk drugs in India and internationally. It offers formulations for parenterals, oral/enterals, topical agents, aerosol, gynecology therapy, orthopedic, and vision care products. Albert David Limited was incorporated in 1938 and is headquartered in Kolkata, India.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.08.
Recent Developments
- Mar 2026 Revenue of ₹333.60 Cr (-3.5% YoY); net profit ₹-1.49 Cr.
- Trailing 12 Months Year-on-year growth — revenue -3.5%, earnings -108.7%.
- 5-Year Trend Long-term compounding — revenue CAGR -0.6%, profit CAGR -34.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -0.63% |
| 1 Year: | -3.52% |
Compounded Profit Growth
| 5 Years: | -34.71% |
| 1 Year: | -108.69% |
Stock Price Performance
| 1 Year: | -21.82% |
| 6 Months: | -5.83% |
| 3 Months: | -2.36% |
| 1 Month: | -3.21% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)46.56 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -0.6% CAGR over 5 years.
- Earnings shrank at -34.7% CAGR over 5 years.
- Trading 25.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ALBERTDAVD Albert David Limited NSEPHARMA | 702.30 | -268.05 | ₹400.81 Cr | 0.71% | 0.78% | -0.38% | -0.63% | -34.71% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,948.80 | 40.77 | ₹4.68 L Cr | 0.83% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 7,315.50 | 75.61 | ₹1.94 L Cr | 0.44% | 18.96% | 15.32% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,952.20 | 87.70 | ₹1.68 L Cr | 0.78% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,981.00 | 66.51 | ₹1.29 L Cr | 0.23% | 19.79% | 20.48% | 15.33% | 33.34% |
| 6 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,440.10 | 22.07 | ₹1.16 L Cr | 0.90% | 14.86% | 11.27% | 7.23% | 11.45% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,137.40 | 22.71 | ₹1.14 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,494.30 | 21.42 | ₹1.14 L Cr | 0.72% | 28.42% | 23.76% | 19.10% | 131.46% |
| 9 | MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA | 1,099.00 | 99.82 | ₹1.07 L Cr | 0.18% | 12.57% | 13.42% | 22.37% | 9.34% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 74.89 Cr | 70.57 Cr | 87.24 Cr | 89.93 Cr | 85.86 Cr |
| Cost of Revenue | - | 29.33 Cr | 25.28 Cr | 30.65 Cr | 27.83 Cr | 30.10 Cr |
| Gross Profit | - | 45.57 Cr | 45.29 Cr | 56.59 Cr | 62.09 Cr | 55.77 Cr |
| Operating Expenses | - | 52.13 Cr | 58.33 Cr | 56.28 Cr | 53.69 Cr | 55.73 Cr |
| Operating Income | - | -6.56 Cr | -13.04 Cr | 31.24 L | 8.40 Cr | 3.37 L |
| EBITDA | - | -9.86 Cr | 11.38 Cr | 39.68 L | 23.22 Cr | -22.08 Cr |
| Interest Expense | - | 13.15 L | 55.48 L | 75.07 L | 89.77 L | 42.91 L |
| Pretax Income | - | -11.81 Cr | 8.44 Cr | -2.58 Cr | 19.90 Cr | -25.23 Cr |
| Tax Provision | - | -1.48 Cr | 50.07 L | 71.96 L | 4.60 Cr | -3.80 Cr |
| Net Income | - | -10.33 Cr | 7.94 Cr | -3.30 Cr | 15.30 Cr | -21.43 Cr |
| Diluted EPS | - | -18.10 | 13.91 | -5.79 | 26.81 | -37.56 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 340.01 Cr | 360.26 Cr | 345.77 Cr | 333.60 Cr |
| Cost of Revenue | - | 125.68 Cr | 128.40 Cr | 116.28 Cr | 113.86 Cr |
| Gross Profit | - | 214.33 Cr | 231.86 Cr | 229.48 Cr | 219.74 Cr |
| Operating Expenses | - | 177.78 Cr | 190.81 Cr | 233.43 Cr | 224.03 Cr |
| Operating Income | - | 36.54 Cr | 41.05 Cr | -3.94 Cr | -4.30 Cr |
| EBITDA | - | 59.62 Cr | 104.32 Cr | 32.61 Cr | 12.92 Cr |
| Interest Expense | - | 34.00 L | 20.72 L | 41.04 L | 2.63 Cr |
| Pretax Income | - | 50.74 Cr | 97.29 Cr | 25.23 Cr | 52.49 L |
| Tax Provision | - | 14.56 Cr | 21.87 Cr | 8.03 Cr | 2.02 Cr |
| Net Income | - | 36.17 Cr | 75.42 Cr | 17.20 Cr | -1.49 Cr |
| Diluted EPS | - | 63.39 | 132.15 | 30.14 | -2.62 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 423.39 Cr | 497.99 Cr | 511.42 Cr | 519.13 Cr |
| Current Assets | - | 304.24 Cr | 371.63 Cr | 354.05 Cr | 374.40 Cr |
| Cash & Equivalents | - | 1.45 Cr | 5.44 Cr | 41.73 L | 29.91 L |
| Inventory | - | 50.68 Cr | 43.61 Cr | 63.90 Cr | 58.27 Cr |
| Receivables | - | 30.33 Cr | 29.33 Cr | 27.37 Cr | 33.92 Cr |
| Total Liabilities | - | 111.82 Cr | 115.01 Cr | 118.93 Cr | 127.60 Cr |
| Current Liabilities | - | 98.94 Cr | 99.05 Cr | 104.18 Cr | 115.43 Cr |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 5.32 Cr | 3.32 Cr | 12.32 Cr | 29.58 Cr |
| Total Equity | - | 311.57 Cr | 382.98 Cr | 392.48 Cr | 391.54 Cr |
| Shares Outstanding | - | 57.07 L | 57.07 L | 57.07 L | 57.07 L |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 10.52 Cr | 45.50 Cr | -28.44 Cr | -7.66 Cr |
| Investing Cash Flow | - | -5.00 Cr | -33.25 Cr | 23.30 Cr | -4.40 Cr |
| Financing Cash Flow | - | -6.36 Cr | -8.27 Cr | 11.03 L | 11.92 Cr |
| Capital Expenditure | - | -5.24 Cr | -10.87 Cr | -14.86 Cr | -29.11 Cr |
| Free Cash Flow | - | 5.28 Cr | 34.63 Cr | -43.29 Cr | -36.77 Cr |
| Net Change in Cash | - | -84.24 L | 3.98 Cr | -5.02 Cr | -13.67 L |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 63.0% | 64.4% | 66.4% | 65.9% |
| Operating Margin % | - | 10.7% | 11.4% | -1.1% | -1.3% |
| Net Margin % | - | 10.6% | 20.9% | 5.0% | -0.4% |
| ROE % | - | 11.6% | 19.7% | 4.4% | -0.4% |
| ROCE % | - | 11.3% | 10.3% | -1.0% | -1.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ALBERTDAVD
Albert David Ltd. Share Price Today - Albert David Ltd. Stock Price Live NSE/BSE - CNBC TV18
<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE8tckZiQWNHZWpGcDFHNHZmTUNZdDdmNk5vNS1FWllQd2VXYzFHR2dsbmhGNnlWeEZEZXhVY1MwR1RWbWFYRVJJR0ZDcEhYcE9rVjVSRjczWkNab0VlTS0wVnRtUmh1Nms1MHRGNUJ4c1dLOG12b2FOcGhhZmpRZw?oc=5" target="_blan…
PRAVEG Stock Price and Chart — NSE:PRAVEG - TradingView
<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE5OUjFjSldvdWZuOUxWNnAtMTBvQlhIRDA0bWwtQlE0eE16eGVRd2lmM0hhSUFuOVdzWFBacGFvV0kwM1E2RDl5a2ZxYUE5dXh4NzhCXzNLVGhrRXc?oc=5" target="_blank">PRAVEG Stock Price and Chart — NSE:PRAVEG</a…
ALBERTDAVD — Frequently Asked Questions
What is the current share price of Albert David Limited (ALBERTDAVD)?
As of 2026-07-15 09:52 IST, Albert David Limited (ALBERTDAVD) trades at ₹702.30 on NSE. Its 52-week range is ₹587.05 to ₹936.84.
What is the market capitalisation of ALBERTDAVD?
Albert David Limited (ALBERTDAVD) has a market capitalisation of ₹400.81 Cr on NSE.
What is the P/E ratio of ALBERTDAVD?
ALBERTDAVD trades at a trailing price-to-earnings (P/E) ratio of -268.05. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 1.02.
Does ALBERTDAVD pay a dividend?
Albert David Limited (ALBERTDAVD) currently offers a dividend yield of 0.71%.
What is the return on equity (ROE) of ALBERTDAVD?
ALBERTDAVD has a return on equity (ROE) of -0.38%. Its return on capital employed (ROCE) is 0.78%.
Is ALBERTDAVD a good stock to buy?
This page provides a data-driven analysis of Albert David Limited (ALBERTDAVD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.